Chuangmei Pharmaceutical (02289.HK) Annual net profit fell 13.16% to 46.27 million yuan, with a final dividend of 0.30 yuan.

Gelonghui March 27 | Creatime Pharmaceutical (02289.HK) announced its annual results. For the year ended December 31, 2025, revenue was RMB 4,384 million, down 1.15% year over year; the group’s net profit attributable to shareholders of the company was RMB 46.27 million, down 13.16% year over year. The group’s basic and diluted earnings per share were RMB 0.4285. The board of directors recommended paying a final dividend of RMB 0.30 per share (including tax) for the year ended December 31, 2025.

During the reporting period, the group adhered to its established operating targets, continued to deepen its presence in the Guangdong market and to expand into surrounding areas, and actively grew its retail terminal network. As of December 31, 2025, the group’s distribution network covered 14,241 customers, including 673 distributors, 9,161 retail pharmacies, and 4,407 hospitals, clinics, health stations, and others. To meet customers’ different needs and enhance customer stickiness, the group strengthened cooperation with well-known manufacturers at home and abroad, improved the variety and scale of primary distributable products, continued to optimize its product mix, introduced high-quality products that are suitable for the market with high gross profit margins, and enriched its product categories. As of December 31, 2025, the group distributed 12,923 product specifications, an increase of 113 compared with the previous year. The group had 1,276 suppliers, including 651 pharmaceutical manufacturers and 625 distribution suppliers, an increase of 70 compared with the previous year.